Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 15;40(11):348.
doi: 10.1007/s11274-024-04162-0.

AVR/I/SSAPDB: a comprehensive & specialised knowledgebase of antimicrobial peptides to combat VRSA, VISA, and VSSA

Affiliations

AVR/I/SSAPDB: a comprehensive & specialised knowledgebase of antimicrobial peptides to combat VRSA, VISA, and VSSA

Rajat Kumar Mondal et al. World J Microbiol Biotechnol. .

Abstract

The rise of multi-drug resistant (MDR) bacteria, especially strains of Staphylococcus aureus like Vancomycin-resistant S. aureus (VRSA), Vancomycin-intermediate S. aureus (VISA), and Vancomycin-susceptible S. aureus (VSSA), poses a severe threat to global health. This situation underscores the urgent need for novel antimicrobial agents to combat these resistant strains effectively. Here, we are introducing the Anti-Vancomycin-Resistant/Intermediate/Susceptible Staphylococcus aureus Peptide Database (AVR/I/SSAPDB), a manually curated comprehensive and specialised knowledgebase dedicated to antimicrobial peptides (AMPs) that target VRSA, VISA, and VSSA with clinical and non-clinical significance. Our database sources data from PubMed, cataloging 491 experimentally validated AMPs with detailed annotations on peptides, activity, and cross-references to external databases like PubMed, UniProt, PDB, and DrugBank. AVR/I/SSAPDB offers a user-friendly interface with simple to advanced and list-based search capabilities, enabling researchers to explore AMPs against VRSA, VISA, and VSSA. We are hoping that this resource will be helpful to the scientific community in developing targeted peptide-based therapeutics, providing a crucial tool for combating VRSA, VISA, and VSSA, and addressing a major public health concern. AVR/I/SSAPDB is freely accessible via any web-browser at URL: https://bblserver.org.in/avrissa/ .

Keywords: AVR/I/SSAPDB; Antimicrobial peptides; MDR bacteria; Vancomycin-intermediate Staphylococcus aureus; Vancomycin-resistant Staphylococcus aureus; Vancomycin-susceptible Staphylococcus aureus.

PubMed Disclaimer

References

    1. Anurag Anand A, Amod A, Anwar S, Sahoo AK, Sethi G, Samanta SK (2023) A comprehensive guide on screening and selection of a suitable AMP against biofilm-forming bacteria. Crit Rev Microbiol 50(5):1–20
    1. Appelbaum PC (2006) The emergence of Vancomycin-intermediate and Vancomycin‐resistant Staphylococcus aureus. Clin Microbiol Infect 12:16–23 - PubMed - DOI
    1. Bamigboye BT, Olowe OA, Taiwo SS (2018) Phenotypic and molecular identification of Vancomycin resistance in clinical Staphylococcus aureus isolates in Osogbo, Nigeria. Eur J Microbiol Immunol 8(1):25–30 - DOI
    1. Bédard F, Fliss I, Biron E (2018) Structure–activity relationships of the bacteriocin bactofencin A and its interaction with the bacterial membrane. ACS Infect Dis 5(2):199–207 - PubMed - DOI
    1. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML (2004) Clinical features associated with bacteremia due to heterogeneous Vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38(3):448–451 - PubMed - DOI

MeSH terms

LinkOut - more resources